Condition: Advanced or Metastatic Solid Tumor · Liver Failure · Sponsor: Gilead Sciences
The goals of this clinical study are to learn more about the safety and dosing of the study drug, sacituzumab govitecan-hziy, in participants with solid tumors and moderate liver problems.
This description comes directly from the study's public registry record.
Gilead Clinical Study Information Center · 1-833-445-3230 (GILEAD-0) · GileadClinicalTrials@gilead.com
Always discuss trial participation with your own doctor first.
| Pacific Shores Medical Group | Long Beach, California, United States | Suspended |
| Christiana Care Health Services | Newark, Delaware, United States | Recruiting |
| University of Maryland | Baltimore, Maryland, United States | Recruiting |
| NEXT Austin | Austin, Texas, United States | Withdrawn |
| Oncology Consultants, P.A. | Houston, Texas, United States | Recruiting |
| The University of Texas M.D. Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| Texas Liver Institute | San Antonio, Texas, United States | Recruiting |
| NEXT Oncology | San Antonio, Texas, United States | Recruiting |
| Institut Bergonie Medical Oncology | Bordeaux, France | Recruiting |
| Centre Leon Berard | Lyon, France | Recruiting |
| Institut de Cancerologie de l'Ouest (ICO) - Saint-Herblain | Saint-Herblain, France | Recruiting |
| Instituto Europeo di Oncologia | Milan, Italy | Recruiting |
+ 3 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04617522